Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma.
about
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastomaSkin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.Polyamines and nonmelanoma skin cancer.The mechanisms by which polyamines accelerate tumor spread.Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitorPolyamine transport as a target for treatment of Pneumocystis pneumonia.Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.Polyamines metabolism and breast cancer: state of the art and perspectives.AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells.A central role for polyamines in microtubule assembly in cells.Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.Cats, Cancer and Comparative OncologyCarcinogen-induced animal models of head and neck squamous cell carcinoma.Evaluation of Polyamine Transport Inhibitors in a Drosophila Epithelial Model Suggests the Existence of Multiple Transport Systems.An overview of polyamine metabolism in pancreatic ductal adenocarcinoma.Cancer cell targeting driven by selective polyamine reactivity with glycine propargyl esters.Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.
P2860
Q26770306-C934F22D-ACC1-495E-9071-B85F68993BD0Q26783914-4F8FC462-E62C-40A3-9702-58C57CFF2EA2Q34603550-98221DB2-D63C-4017-AF8A-D6214921A547Q35505118-81AE61BB-339C-45C3-B8B4-2FDC10D45438Q35580905-0B0E7082-4273-4CEB-880F-E9AB8B1B2CC9Q37271598-B340668D-6703-4FED-81CC-08FAC5FF8BC9Q37450672-97BD10AA-1A77-4895-9A2A-C565F9F644A0Q37605450-CBA7B7DD-FAF1-4D31-8A93-1E9D4C8AE50BQ38257840-082A935C-C2FF-4328-B9FD-8019377E8063Q39185908-CDF1934A-F8EB-4F52-BB32-3F4DDAD4BE9EQ39496558-9433C3C4-5A96-44DF-9344-DD962DFA6F0AQ39696646-11C4D680-6DF4-4417-BDC8-601C904E5434Q41107342-90868AAC-EBCB-4A63-98B7-8B9FD1F66FD9Q41347219-A5D50907-E34F-4477-9FD1-7921758F8BFBQ42698528-E291572E-5D48-408B-AF7F-1DDC9C99A804Q42726592-44905A58-3D53-4D3C-BD48-ADBA912C1BB5Q48307540-8CB492A5-CDAE-4482-B647-60330CD6AD29Q48310001-9E4898A4-4BD5-412E-AD8C-60973EC9CD2EQ48317030-881FFD5B-C9B5-4675-B0B8-3B506B44465BQ48506495-DC2D37A2-6D13-4845-84C2-1F61D6A6ED61
P2860
Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@en
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@nl
type
label
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@en
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@nl
prefLabel
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@en
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@nl
P2093
P356
P1476
Combination therapy with 2-dif ...... urine squamous cell carcinoma.
@en
P2093
Andres Klein-Szanto
David W Boorman
Mark R Burns
Reitha S Weeks
Thomas G O'Brien
P304
P356
10.1002/IJC.21621
P577
2006-05-01T00:00:00Z